Search by Drug Name or NDC

NDC 57894-0501-01 Rybrevant 350 mg/1 Details

Rybrevant 350 mg/1

Rybrevant is a INTRAVENOUS INJECTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Janssen Biotech, Inc.. The primary component is AMIVANTAMAB.

MedlinePlus Drug Summary

Amivantamab-vmjw injection is used to treat a certain type of non-small cell lung cancer (NSCLC) that spread to other parts of the body or cannot be removed by surgery, and has worsened either during or after treatment with platinum chemotherapy medications. Amivantamab-vmjw injection is in a class of medications called bispecific antibodies. It works by helping your immune system to slow or stop the growth of cancer cells.

Related Packages: 57894-0501-01
Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Amivantamab-vmjw Injection

Product Information

NDC	57894-0501
Product ID	57894-501_0e9bd298-6994-1bbb-e063-6394a90a3d70
Associated GPIs	21359710802020
GCN Sequence Number	082306
GCN Sequence Number Description	amivantamab-vmjw VIAL 350 MG/7ML INTRAVEN
HIC3	V15
HIC3 Description	ANTINEOPLASTIC - EGFR AND MET RECEPTOR INHIB, MAB
GCN	49686
HICL Sequence Number	047385
HICL Sequence Number Description	AMIVANTAMAB-VMJW
Brand/Generic	Brand
Proprietary Name	Rybrevant
Proprietary Name Suffix	n/a
Non-Proprietary Name	Amivantamab
Product Type	HUMAN PRESCRIPTION DRUG
Dosage Form	INJECTION
Route	INTRAVENOUS
Active Ingredient Strength	350
Active Ingredient Units	mg/1
Substance Name	AMIVANTAMAB
Labeler Name	Janssen Biotech, Inc.
Pharmaceutical Class	n/a
DEA Schedule	n/a
Marketing Category	BLA
Application Number	BLA761210
Listing Certified Through	2025-12-31

Package

NDC 57894-0501-01 (57894050101)

Pricing Information	N/A
NDC Package Code	57894-501-01
Billing NDC	57894050101
Package	1 VIAL, SINGLE-USE in 1 CARTON (57894-501-01) / 1 INJECTION in 1 VIAL, SINGLE-USE (57894-501-00)
Marketing Start Date	2021-05-21
NDC Exclude Flag	N